Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.45 |
| ▸ | FLT3 | P36888 | 3/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.37 |
| ▸ | EGFR | P00533 | 3/20 | 0.36 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390515 | 0.89 | GPR119 (0.59) | GPR119CYP2C9 | |
| SCHEMBL13685341 | 0.80 | GPR119 (0.53) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL5264014 | 0.78 | GPR119 (0.46) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL1832092 | 0.76 | GPR119 (0.44) | GPR119FLT3CDK2CDK6CYP2C9 | |
| SCHEMBL1070555 | 0.72 | GPR119 (0.47) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL5048764 | 0.72 | GPR119 (0.49) | GPR119FLT3CDK2CDK6ERBB2 | |
| SCHEMBL1837819 | 0.72 | KDM5B (0.41) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL5264283 | 0.72 | GPR119 (0.62) | GPR119FLT3CDK2CDK6CYP2C9 | |
| SCHEMBL1830976 | 0.72 | GPR119 (0.45) | GPR119FLT3CDK2CDK6EGFR | |
| SCHEMBL5046848 | 0.70 | GPR119 (0.44) | GPR119FLT3CDK2CDK6ERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1758565-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | Arena Pharmaceuticals, Inc. (US) | 2007-03-07 | — | — | EP | disclosed |
| WO-2006076231-A2 | COMBINATION THERAPY FOR THE TREATMENT OF DIABETES AND CONDITIONS RELATED THERETO AND FOR THE TREATMENT OF CONDITIONS AMELIORATED BY INCREASING A BLOOD GLP-1 LEVEL | ARENA PHARMACEUTICALS, INC. (US) | 2006-07-20 | — | — | WO | disclosed |